Cts-Clinical and Translational Science最新文献_第7页

Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase-4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas 与磺脲类药物相比，使用二肽基肽酶-4抑制剂或噻唑烷二酮类药物的2型糖尿病患者患银屑病的风险较低

IF 3.1 3区医学

Cts-Clinical and Translational Science Pub Date : 2025-03-12 DOI: 10.1111/cts.70177

Wei-Sheng Chen, Tzu-Min Lin, Yu-Sheng Chang, Yu-Chuan Shen, Hui-Ching Hsu, Tzu-Tung Kuo, Shu-Chuan Chen, Jin-Hua Chen, Chi-Ching Chang

{"title":"Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase-4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas","authors":"Wei-Sheng Chen, Tzu-Min Lin, Yu-Sheng Chang, Yu-Chuan Shen, Hui-Ching Hsu, Tzu-Tung Kuo, Shu-Chuan Chen, Jin-Hua Chen, Chi-Ching Chang","doi":"10.1111/cts.70177","DOIUrl":"https://doi.org/10.1111/cts.70177","url":null,"abstract":"The risk of psoriasis in diabetic patients has rarely been explored. This study aims to compare the risk of incident psoriasis in patients with Type 2 diabetes (T2D) who initiate dipeptidyl peptidase-4 inhibitors (DPP-4is) or thiazolidinediones (TZDs) with those who initiate sulfonylureas, the most common second-line glucose-lowering therapy, in addition to metformin monotherapy. This sequential, propensity-score-matched, new-user comparative effectiveness study utilized a target trial emulation framework. It included adults with T2D receiving metformin monotherapy, using data from 2006 to 2015 from a general population database in Taiwan. The primary outcome was the incidence of psoriasis, determined through diagnoses recorded in urgent care, hospital, and outpatient department records. Cox proportional hazards and Poisson regressions with 1:4 propensity score matching was employed to evaluate the risk factors for psoriasis after adjusting for comorbidities and the use of other medications. In 49,810 propensity score-matched adults with T2D (27,630 men [55.4%]; mean age 57.5 years) identified in the database, the incidence rate of psoriasis in DPP-4i users was 188 cases per 100,000 person-years, lower than in sulfonylurea users (467 cases per 100,000 person-years), with a hazard ratio(HR) of 0.422 (95% CI, 0.273–0.716). For the TZD vs. sulfonylurea comparison, the HR was 0.35, but the smaller matched dataset resulted in wide confidence intervals. The findings suggest that the use of DPP-4is is associated with a lower risk of psoriasis compared to sulfonylureas in patients with T2D. These results can guide the selection of glucose-lowering therapies in T2D patients who are at risk of developing psoriasis.","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"18 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70177","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143602665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of Food Effect and pH-Dependent Drug–Drug Interactions of Fruquintinib in Healthy Subjects 在健康受试者中评价fruquininib的食物效应和ph依赖的药物-药物相互作用

IF 3.1 3区医学

Cts-Clinical and Translational Science Pub Date : 2025-03-12 DOI: 10.1111/cts.70168

Martha Gonzalez, Zhao Yang, William R. Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien

{"title":"Assessment of Food Effect and pH-Dependent Drug–Drug Interactions of Fruquintinib in Healthy Subjects","authors":"Martha Gonzalez, Zhao Yang, William R. Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien","doi":"10.1111/cts.70168","DOIUrl":"https://doi.org/10.1111/cts.70168","url":null,"abstract":"This two-sequence, three-period study (NCT04645940) was designed to evaluate the effect of food and concomitant rabeprazole, a proton pump inhibitor, on the pharmacokinetics (PK) and safety of fruquintinib and its metabolite M11 after a single oral dose of fruquintinib 5 mg in healthy subjects. In the food effect treatment periods, 14 subjects were randomized in a 1:1 ratio utilizing a two-sequence (fed/fasted vs. fasted/fed), two-period, cross-over design. Fruquintinib was administered on Day 1 (Period 1) and Day 15 (Period 2). In the drug-interaction period (Period 3), all subjects received rabeprazole 40 mg 1 h prior to fruquintinib under fasted conditions, following a 6-day lead-in of rabeprazole 40 mg once daily. PK samples to measure fruquintinib and M11 were collected pre-dose and over 168 h after fruquintinib dosing. Administration of fruquintinib with a high-fat meal resulted in similar systemic exposure compared with fasted conditions. In addition, coadministration of fruquintinib with rabeprazole resulted in similar exposure compared with fruquintinib alone. For both evaluations, 90% confidence intervals for the ratio of geometric least square mean of the area under the curve and peak concentration for fruquintinib and M11 were entirely within 80%–125% bounds. The study results showed no effects of food or rabeprazole on fruquintinib PK, and support that fruquintinib can be taken without regard to food or concurrent gastric acid-reducing agents.","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"18 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70168","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143602580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium 建立循环肿瘤DNA分析和分子残留疾病的通用词典：来自BLOODPAC联盟的见解

IF 3.1 3区医学

Cts-Clinical and Translational Science Pub Date : 2025-03-11 DOI: 10.1111/cts.70185

Andrew G. Hadd, Angela Silvestro, Brittany Avin McKelvey, Jonathan Baden, Christina Bormann Chung, Ben Brown, Fernando Cruz-Guilloty, James Godsey, Gregory Jones, Cheng-Ho Jimmy Lin, Dorys Lopez Ramos, Daniel Norton, Melanie R. Palomares, Carol Pena, Thereasa Rich, Angel Rodriguez, Mark Stewart, Diana Merino Vega, Lauren C. Leiman

{"title":"Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium","authors":"Andrew G. Hadd, Angela Silvestro, Brittany Avin McKelvey, Jonathan Baden, Christina Bormann Chung, Ben Brown, Fernando Cruz-Guilloty, James Godsey, Gregory Jones, Cheng-Ho Jimmy Lin, Dorys Lopez Ramos, Daniel Norton, Melanie R. Palomares, Carol Pena, Thereasa Rich, Angel Rodriguez, Mark Stewart, Diana Merino Vega, Lauren C. Leiman","doi":"10.1111/cts.70185","DOIUrl":"https://doi.org/10.1111/cts.70185","url":null,"abstract":"The use of a liquid biopsy to assess molecular residual disease (MRD) of solid tumors holds significant promise for improving outcomes for patients with cancer. Liquid biopsies are a minimally invasive approach for the identification of circulating tumor biomarkers through a simple blood sample. Assays capable of detecting MRD through analysis of circulating tumor DNA (ctDNA) are rapidly evolving for clinical study applications and therapeutic interventions. To address these opportunities, BLOODPAC—a multi-disciplinary consortium representing stakeholders from public, industry, academia, and regulatory agencies—formulated a lexicon that provides a shared framework and clear definitions using liquid biopsies for solid tumor MRD with an emphasis on ctDNA detection. The terms in the lexicon are categorized under general MRD, ctDNA testing methodologies, reporting results, and acquisition timepoints, including examples of current and potential clinical use cases for MRD tests. The overall goal is to provide a unified language and approaches to solid tumor MRD to advance applications of these technologies, allow data aggregation to strengthen future evidence, and facilitate regulatory approvals, leading to the use of liquid biopsy as an early endpoint in clinical trials. We believe that a common set of terminology and methods for solid tumor MRD can improve understanding and appropriate use of testing, accelerate clinical development, and improve outcomes for cancer patients.","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"18 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70185","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143602769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Tutorial and Use Case Example of the eXtreme Gradient Boosting (XGBoost) Artificial Intelligence Algorithm for Drug Development Applications 药物开发应用的极端梯度增强（XGBoost）人工智能算法的教程和用例示例

IF 3.1 3区医学

Cts-Clinical and Translational Science Pub Date : 2025-03-11 DOI: 10.1111/cts.70172

Matthew Wiens, Alissa Verone-Boyle, Nick Henscheid, Jagdeep T. Podichetty, Jackson Burton

引用次数: 0

Buprenorphine's Effect on the Human Immune System and Inflammation 丁丙诺啡对人体免疫系统和炎症的影响

IF 3.1 3区医学

Cts-Clinical and Translational Science Pub Date : 2025-03-10 DOI: 10.1111/cts.70180

Samuel D. Shin, Rachel Branning, Michele McGinnis, Alexandra Shin, Ming-Fen Ho, Victor M. Karpyak, Tyler Oesterle

{"title":"Buprenorphine's Effect on the Human Immune System and Inflammation","authors":"Samuel D. Shin, Rachel Branning, Michele McGinnis, Alexandra Shin, Ming-Fen Ho, Victor M. Karpyak, Tyler Oesterle","doi":"10.1111/cts.70180","DOIUrl":"https://doi.org/10.1111/cts.70180","url":null,"abstract":"Opioid use disorder is a persistent epidemic despite several FDA-approved medications for its treatment. While the pathogenesis of opioid use disorder has been classically attributed to dopamine pathways in the brain, there is emerging evidence and interest surrounding the role of inflammation and inflammatory signaling in its development and treatment. Buprenorphine has become the most prescribed medication for opioid use disorder, largely due to its ease of access and tolerability. This review aimed to better characterize contemporary knowledge of how buprenorphine modulates the human immune system and inflammatory functions in this population. A comprehensive review was conducted using 11 key databases, including Embase, MEDLINE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. This review captured 8177 records, and 14 studies were ultimately selected for inclusion and discussion in this review. Notably, all 14 clinical studies evaluated buprenorphine's effect on the peripheral immune system, and the majority of the studies supported the notion that initiation and maintenance of buprenorphine restore immune suppression caused by opioid use disorder. In addition, we discuss how recent and ongoing work utilizing advanced imaging and cellular technologies is advancing the understanding of how buprenorphine affects the immune and inflammatory signaling in the brain.","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"18 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70180","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143595229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects 新型抗纤维化小分子SC1011（苏非尼酮）的安全性、耐受性和药代动力学在健康受试者中的1期研究

IF 3.1 3区医学

Cts-Clinical and Translational Science Pub Date : 2025-03-10 DOI: 10.1111/cts.70179

Yun Liu, Xiaoning Chen, Huimin Tang, Fan Jiang, Yaqin Tang, Huijuan Zhu, Yanping Du, Hongjie Qian, Shuyun Liu, Xiaoshu Sun, Bin Zan, Yuexia Zeng, Yun Li, Zhen Ge, Yongguo Li, Zhongqi Yang

{"title":"Safety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects","authors":"Yun Liu, Xiaoning Chen, Huimin Tang, Fan Jiang, Yaqin Tang, Huijuan Zhu, Yanping Du, Hongjie Qian, Shuyun Liu, Xiaoshu Sun, Bin Zan, Yuexia Zeng, Yun Li, Zhen Ge, Yongguo Li, Zhongqi Yang","doi":"10.1111/cts.70179","DOIUrl":"https://doi.org/10.1111/cts.70179","url":null,"abstract":"SC1011 (sufenidone) is a novel pyridone derivative with therapeutic potential for idiopathic pulmonary fibrosis (IPF). Two Phase 1 studies evaluated the safety and pharmacokinetics of single (SAD) and multiple ascending doses (MAD) of SC1011 immediate-release (IR) and modified-release (MR) oral formulations in healthy adult subjects. In Phase 1a, subjects were randomized to receive oral SC1011 IR or placebo in SAD (50 mg-300 mg) or MAD (100 mg and 200 mg) twice daily for 7 days. The Phase 1b study consisted of three treatment groups that received 100, 150, or 200 mg SC1011 MR twice daily for 7 days. SC1011 IR was absorbed rapidly (mean time to maximum concentration, Tmax ≤ 1 h) and eliminated rapidly (mean terminal half-life, t1/2: 1.23–2.64 h) following 50–300 mg single-dose administrations. Reduced maximum plasma concentration (Cmax), delayed Tmax, and comparable total exposure were observed with the MR formulation compared with the IR formulation. Both formulations demonstrated dose-proportional pharmacokinetics at the applied dose ranges, and no obvious accumulation of systemic exposure was observed upon repeated administration. All treatment-emergent adverse events (TEAEs) with both formulations were mild or moderate in severity, and gastrointestinal reactions were the most frequently reported TEAEs. The tolerability of SC1011 was markedly improved with the MR formulation. Exposure–adverse event (AE) analysis with the most frequent AEs identified Cmax rather than total exposure as a good predictor of AEs. Compared to the IR formulation, SC1011 MR demonstrated improved exposure and tolerability, supporting its further development in patients with IPF.","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"18 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70179","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143594847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative Effectiveness of Dual Biologic Therapy and Biologic Small-Molecule Therapy for Refractory Inflammatory Bowel Disease: A Retrospective Single-Center Study 双生物疗法和小分子生物疗法治疗难治性炎症性肠病的比较疗效：一项回顾性单中心研究

IF 3.1 3区医学

Cts-Clinical and Translational Science Pub Date : 2025-03-10 DOI: 10.1111/cts.70198

Fan Yin, Xiaolei Liu, Dongdong He, Songbo Li, Xin Feng, Yongquan Shi, Min Chen

{"title":"Comparative Effectiveness of Dual Biologic Therapy and Biologic Small-Molecule Therapy for Refractory Inflammatory Bowel Disease: A Retrospective Single-Center Study","authors":"Fan Yin, Xiaolei Liu, Dongdong He, Songbo Li, Xin Feng, Yongquan Shi, Min Chen","doi":"10.1111/cts.70198","DOIUrl":"https://doi.org/10.1111/cts.70198","url":null,"abstract":"Patients with refractory inflammatory bowel disease (IBD) face difficulty in the treatment strategy. Combined advanced targeted therapies may obtain higher therapeutic efficacy. However, few studies compare the efficacy and safety of dual biologic therapy (DBT) with biologic small-molecule therapy (BMT) for refractory IBD. We aimed to compare the effectiveness of DBT with BMT. We retrospectively analyzed the data of patients with refractory IBD treated with DBT (n = 22) or BMT (n = 21). The primary outcome was the clinical remission rate at week 12. Secondary outcomes included the clinical response rate, endoscopic response rate, endoscopic remission rate, colectomy rate, and rate of adverse events (AEs) at week 12. At week 12, the clinical remission rates in the DBT group and BMT group were 22.7% and 28.6%, respectively. No statistically significant difference was observed between the two groups (p = 0.661). There were also no statistically significant differences between the DBT group and BMT group in the clinical response rate (68.2% vs. 71.4%, p = 0.817), endoscopic response rate (66.7% vs. 68.8%, p = 1.000), endoscopic remission rate (4.8% vs. 18.8%, p = 0.296) and colectomy rate (4.5% vs. 23.8%, p = 0.167). Two patients (9.5%) in the BMT group and no patients in the DBT group experienced AEs. However, the difference was not statistically significant (p = 0.233). In conclusion, this study revealed that there may be similar effectiveness and safety of DBT and BMT for patients with refractory IBD. Further multi-center, prospective randomized controlled trials are necessary to confirm this conclusion.","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"18 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70198","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143594845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Japanese Phase 1 Study for Global Development of Anti-TL1A Antibody PF-06480605: A Randomized, Placebo-Controlled, Single-Ascending Dose Study 日本抗tl1a抗体PF-06480605全球开发的1期研究：随机、安慰剂对照、单次递增剂量研究

IF 3.1 3区医学

Cts-Clinical and Translational Science Pub Date : 2025-03-10 DOI: 10.1111/cts.70187

Kei Fukuhara, Srividya Neelakantan, Kenichi Furihata, Hirotoshi Yuasa, Nanzhi Shi, Yuichi Yamamoto, Kenneth E. Hung

{"title":"Japanese Phase 1 Study for Global Development of Anti-TL1A Antibody PF-06480605: A Randomized, Placebo-Controlled, Single-Ascending Dose Study","authors":"Kei Fukuhara, Srividya Neelakantan, Kenichi Furihata, Hirotoshi Yuasa, Nanzhi Shi, Yuichi Yamamoto, Kenneth E. Hung","doi":"10.1111/cts.70187","DOIUrl":"https://doi.org/10.1111/cts.70187","url":null,"abstract":"PF-06480605, a fully human IgG1 monoclonal antibody targeting tumor necrosis factor α-like ligand 1A (TL1A), has demonstrated acceptable safety and the potential as an effective treatment for inflammatory bowel disease in phase 1/2a studies. To facilitate future clinical development in Japan and China, a Japan local phase 1 study was designed in consultation with the Japan regulatory authority. In addition to fulfilling Japan regulatory requirements, this study will bring operational efficiency and speed to global and China development by evaluating PF-06480605 in Japanese healthy adults prior to a China local phase 1 study as required by the China regulatory authority. This phase 1, randomized, double-blind, placebo-controlled, single-dose escalating study investigated the safety, tolerability, immunogenicity, pharmacokinetics (PK), and pharmacodynamics of PF-06480605 in Japanese healthy adults assigned to receive a single subcutaneous (SC) dose of PF-06480605 150 mg (N = 6), 450 mg (first-in-human dose level, N = 6), or placebo (N = 4). PF-06480605 was well tolerated and absorbed slowly with a median Tmax of 217.5 h for both 150 and 450 mg doses. Mean t1/2 was 18.4 and 19.1 days for 150 and 450 mg, respectively. Exposure parameters showed dose proportionality. No ethnic differences in PF-06480605 PK were observed. Serum TL1A levels increased in a dose-dependent manner. Immunogenicity was high with 100% of anti-PF-06480605 antibody formulation. This study satisfied the Japan regulatory requirements, while the favorable tolerability and PK of 450 mg SC in Japanese contributed to a waiver of the 150 mg SC cohort in the China local phase 1 study. NCT04269538.","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"18 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70187","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143594846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Agents for Change: Artificial Intelligent Workflows for Quantitative Clinical Pharmacology and Translational Sciences 变革的代理人：定量临床药理学和转化科学的人工智能工作流程

IF 3.1 3区医学

Cts-Clinical and Translational Science Pub Date : 2025-03-08 DOI: 10.1111/cts.70188

Mohamed H. Shahin, Srijib Goswami, Sebastian Lobentanzer, Brian W. Corrigan

{"title":"Agents for Change: Artificial Intelligent Workflows for Quantitative Clinical Pharmacology and Translational Sciences","authors":"Mohamed H. Shahin, Srijib Goswami, Sebastian Lobentanzer, Brian W. Corrigan","doi":"10.1111/cts.70188","DOIUrl":"https://doi.org/10.1111/cts.70188","url":null,"abstract":"Artificial intelligence (AI) is making a significant impact across various industries, including healthcare, where it is driving innovation and increasing efficiency. In the fields of Quantitative Clinical Pharmacology (QCP) and Translational Sciences (TS), AI offers the potential to transform traditional practices through the use of agentic workflows—systems with different levels of autonomy where specialized AI agents work together to perform complex tasks, while keeping “human in the loop.” These workflows can simplify processes, such as data collection, analysis, modeling, and simulation, leading to greater efficiency and consistency. This review explores how these AI-powered agentic workflows can help in addressing some of the current challenges in QCP and TS by streamlining pharmacokinetic and pharmacodynamic analyses, optimizing clinical trial designs, and advancing precision medicine. By integrating domain-specific tools while maintaining data privacy and regulatory standards, well-designed agentic workflows empower scientists to automate routine tasks and make more informed decisions. Herein, we showcase practical examples of AI agents in existing platforms that support QCP and biomedical research and offer recommendations for overcoming potential challenges involved in implementing these innovative workflows. Looking ahead, fostering collaborative efforts, embracing open-source initiatives, and establishing robust regulatory frameworks will be key to unlocking the full potential of agentic workflows in advancing QCP and TS. These efforts hold the promise of speeding up research outcomes and improving the efficiency of drug development and patient care.","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"18 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70188","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetics and Pharmacodynamics of KT-474, a Novel Selective Interleukin-1 Receptor–Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults 新型选择性白介素-1受体相关激酶4 （IRAK4）降解剂KT-474在健康成人体内的药代动力学和药效学

IF 3.1 3区医学

Cts-Clinical and Translational Science Pub Date : 2025-03-08 DOI: 10.1111/cts.70181

Sagar Agarwal, Alice A. McDonald, Veronica Campbell, Dapeng Chen, Jeff Davis, Haojing Rong, Aimee Mishkin, Anthony Slavin, Ashwin Gollerkeri, Jared A. Gollob

{"title":"Pharmacokinetics and Pharmacodynamics of KT-474, a Novel Selective Interleukin-1 Receptor–Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults","authors":"Sagar Agarwal, Alice A. McDonald, Veronica Campbell, Dapeng Chen, Jeff Davis, Haojing Rong, Aimee Mishkin, Anthony Slavin, Ashwin Gollerkeri, Jared A. Gollob","doi":"10.1111/cts.70181","DOIUrl":"https://doi.org/10.1111/cts.70181","url":null,"abstract":"Interleukin-1 receptor–associated kinase 4 (IRAK4), a key component of the Myddosome complex, mediates signaling through toll-like and interleukin-1 receptors. KT-474, a heterobifunctional IRAK4 degrader, was evaluated in a randomized, double-blind, placebo-controlled Phase 1 trial (NCT04772885) in single (25, 75, 150, 300, 600, 1000, and 1600 mg) and multiple (25, 50, 100, and 200 mg once daily [QD] for 14 days; or 200 mg twice weekly) ascending doses in healthy subjects. The pharmacokinetics of KT-474 and its diastereomers, the pharmacodynamics of KT-474, and the effect of food on KT-474 pharmacokinetics and the pharmacokinetic–pharmacodynamic analysis are presented as additional analyses to supplement the Ackerman et al. publication. KT-474 showed delayed absorption and prolonged elimination. Plasma exposure increased less than dose-proportionally, with single-dose exposure plateauing after the 1000 mg dose. Steady state was achieved after 7 days of daily dosing and resulted in a 3- to 4-fold accumulation in exposure. A significant food effect was observed at the 600 mg dose, with exposure increasing up to 2.57-fold when KT-474 was administered with a high-fat meal. Urinary excretion of KT-474 was < 1%. KT-474 demonstrated robust IRAK4 degradation in blood, with mean reductions of up to 98% observed at the 50–200 mg QD doses, as well as inhibition of ex vivo induction of a broad array of cytokines and chemokines by stimulants lipopolysaccharides and R848. Analysis of the relationship between plasma KT-474 concentration and IRAK4 reduction in blood indicated that plasma concentrations of 4.1–5.3 ng/mL would yield 80% IRAK4 reductions.","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"18 3","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70181","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0